A 12-week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of Lactiplantibacillus plantarum NCHBL-004 on reducing body fat

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009308

Enrollment

100

Registered

2024-04-05

Start date

2024-01-24

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : Treatment: Lactiplantibacillus plantarum NCHBL-004 Dose: 1x10^9 CFU/day (oral, once a day) Period: 12 weeks Treatment vs Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: BMI 25 ~ 30 kg/m2

Exclusion criteria

Exclusion criteria: A person currently under treatment for severe cardiovascular, immune, respiratory, gastrointestinal/hepatic and biliary systems, kidney and urinary systems, nervous systems, psychotropic, infectious diseases and malignant tumors. A person who has had obesity surgery within a year. A person who has taken a drug that affects his or her weight within one month.

Design outcomes

Primary

Measure	Time frame
Body fat mass	—

Secondary

Measure	Time frame
Rate of body fat mass, Total fat mass;Body weight, Body Mass Index(BMI);Waist and hip circumference, waist/hip circumference ratio;Total abdominal fat area, visceral fat area, subcutaneous fat area, visceral/subcutaneous fat area ratio;Blood Lipid;Assessment of improvement in bowel symptoms (ROME IV);Survey of Intestinal Health Symptoms	—

Countries

Korea, Republic of

Contacts

Public ContactChaemin Baeg

Global Medical Research Center

cm3690@gmrc.co.kr+82-70-4139-0796

Outcome results